A retrospective study of cholinesterase inhibitors for Alzheimer's disease: Cerebrovascular disease as a predictor of patient outcomes

Current Medical Research and Opinion

Volumn 24, Issue 12, 2008, Pages 3287-3294

  Charbonneau, Claudie ^a   Massoud, Fadi ^a   Dorais, Marc ^a   LeLorier, Jacques ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Centre Hospitalier   (Canada)

Author keywords

Administrative database; Alzheimer's disease; Cerebrovascular disease; Cholinesterase inhibitors; Dementia

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEATH; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME; OUTCOME ASSESSMENT; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT WITHDRAWAL; COHORT ANALYSIS; FACTUAL DATABASE; MORTALITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 62349113727     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802417713     Document Type: Article

References (33)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-2117 (Pubitemid 41797645)
2. Sicras A, Rejas J, Arco S, et al. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting. Dement Geriatr Cogn Disord 2005;19:305-315 (Pubitemid 40663325)
3. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006;21:175-181
4. McDowell I, Hill G, Lindsay J, et al. Canadian study of health and aging - study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913 (Pubitemid 24144100)
5. Lilienfeld S, Kurz A. Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine. Alzheimer's Dis Vasc Etiol Pathol 2002;977:487-492 (Pubitemid 35418193)
6. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract 2003;57:219-223 (Pubitemid 36511782)
7. Bennett D. Public health importance of vascular dementia and Alzheimer's disease with cerebrovascular disease. Int J Clin Pract 2001;120:41-48
8. Fillit H, Hill J. The costs of vascular dementia: a comparison with Alzheimer's disease. J Neurol Sci 2002;203:35-39 (Pubitemid 35291186)
9. Roman G. Managing Vascular Dementia: concepts, Issues and Management. London: Science Press, 2003
10. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16:203-212 (Pubitemid 35434796)
11. Selnes OA, Vinters HV. Vascular cognitive impairment. Nature Clin Pract Neurol 2006;2:538-547 (Pubitemid 44445810)
12. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Eng J Med 2001;344:1111-1116 (Pubitemid 32285231)
13. Aguero-Torres H, Fratiglioni L, Guo Z, et al. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52:737-743 (Pubitemid 29361449)
14. Aevarsson O, Svanborg A, Skoog I. Seven-year survival rate after age 85 years - relation to Alzheimer disease and vascular dementia. Arch Neurol 1998;55:1226 (Pubitemid 28427494)
15. Tatemichi TK, Paik M, Bagiella E, et al. Dementia after stroke is a predictor of long-term survival. Stroke 1994;25:1915-1919 (Pubitemid 24291272)
16. Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?. Am J Geriatr Pharmacother 2005;3:1-7 (Pubitemid 41122352)
17. Brashear HR. Galantamine in the treatment of vascular dementia. Int Psychogeriatr 2003;15:187-193 (Pubitemid 37175189)
18. Schindler RJ. Dementia with cerebrovascular disease: the benefits of early treatment. Eur J Neurol 2005;12:17-21 (Pubitemid 41495146)
19. Hux MJ, O'Brien RJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and cost of caring. Can Med Assoc J 1998;459:457-465 (Pubitemid 28454314)
20. Rockwood K, Brown M, Merry H, et al. Societal costs of vascular cognitive impairment in older adults. Stroke 2002;33:1605-1609 (Pubitemid 34619966)
21. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiologic research - the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009
22. Vonkorff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
23. Lojkowska W, Ryglewicz D, Jedrzejczak T, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003;216:119-126 (Pubitemid 37371876)
24. Gauthier S. Alzheimer's Disease in Primary Care. London: Informa Healthcare: 1999
25. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in vascular dementia. Expert Opin Pharmacother 2004;5:1399-1410 (Pubitemid 38885797)
26. Freo U, Pizzolato G, Carbonin C, et al. Effects of the acetylcholinesterase inhibitor rivastigmine in vascular dementia: results from a prospective pilot study. J Neurol Sci 2002;00:203-204
27. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in vascular dementia. Expert Opin Pharmacother 2004;5:1399-1410 (Pubitemid 38885797)
28. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-1327 (Pubitemid 41140736)
29. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-789 (Pubitemid 36995254)
30. Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:58-67 (Pubitemid 38180693)
31. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-446 (Pubitemid 34855303)
32. Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004;20:1747-1752 (Pubitemid 39611933)
33. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 2004;11:e274-85 (Pubitemid 46333124)